| PUBLICATIONS (Ranked by Impact Factor of the Journal) | Commensal Microbiota and Myelin Autoantigen Cooperate to Trigger Autoimmune Demyelination Using the relapsing–remitting mouse model of spontaneously developing experimental autoimmune encephalomyelitis, here scientists show that the commensal gut flora—in the absence of pathogenic agents—is essential in triggering immune processes, leading to a relapsing–remitting autoimmune disease driven by myelin-specific CD4+ T cells. [Nature] Abstract Expression of A20 by Dendritic Cells Preserves Immune Homeostasis and Prevents Colitis and Spondyloarthritis Here researchers show that mice lacking the ubiquitin-editing molecule A20 specifically in dendritic cells (DCs) spontaneously showed DC activation and population expansion of activated T cells. [Nat Immunol] Abstract Expression of Type I Interferon by Splenic Macrophages Suppresses Adaptive Immunity During Sepsis Here, researchers show that TLR4 is the key immune sensing receptor to initiate paralysis of T-cell immunity after bacterial sepsis. [EMBO J] Abstract Regulatory T Cells Inhibit Acute IFN-γ Synthesis Without Blocking T-Helper Cell Type 1 (Th1) Differentiation via a Compartmentalized Requirement for IL-10 Scientists developed in vitro and in vivo models that enabled the direct test of regulatory T cell regulation of T-helper cell type 1 differentiation. [Proc Natl Acad Sci USA] Abstract Cd8 Enhancer E8I and Runx Factors Regulate CD8α Expression in Activated CD8+ T Cells Here researchers demonstrate a unique transcriptional program regulating CD8 expression during CD8+ effector T-cell differentiation. [Proc Natl Acad Sci USA] Abstract Tetherin Is a Key Effector of the Antiretroviral Activity of Type I Interferon In Vitro and In Vivo Researchers find that tetherin markedly inhibits the replication of Moloney murine leukemia virus and is required for the antiretroviral activity of IFNα to be fully manifested in vitro. [Proc Natl Acad Sci USA] Abstract Coordinated Regulation of Lymph Node Vascular–Stromal Growth First by CD11c+ Cells and Then by T and B Cells Researchers show that blood vascular, lymphatic, and fibroblastic reticular cell growth are coordinately regulated and identify two distinct phases of vascular–stromal growth—an initiation phase, characterized by upregulated vascular–stromal proliferation, and a subsequent expansion phase. [J Immunol] Abstract The Actin Regulatory Protein HS1 Is Required for Antigen Uptake and Presentation by Dendritic Cells Scientists show that dendritic cells from HS1−/− mice differentiate normally and display normal LPS-induced upregulation of surface markers and cytokines. [J Immunol] Abstract NK-Like T Cells and Plasma Cytokines, but Not Anti-Viral Serology, Define Immune Fingerprints of Resilience and Mild Disability in Exceptional Aging Since immunity is vital to individual fitness, investigators examined immunologic fingerprint(s) of highly functional elders. [PLoS One] Abstract | Press Release Antibacterial Role for Natural Killer Cells in Host Defense to Bacillus Anthracis To determine a potential role for natural killer (NK) cells in immunity to B. anthracis, researchers utilized primary human and murine NK cells, in vitro assays, and in vivo NK cell depletion in a murine model of inhalational anthrax. [Infect Immun] Abstract | Press Release |
| INDUSTRY NEWS | Biogen Idec and Portola Pharmaceuticals Announce Global Collaboration for Oral Syk Inhibitor Program Targeting Autoimmune and Inflammatory Diseases Biogen Idec and Portola Pharmaceuticals, Inc. announced that they have entered into an exclusive, worldwide collaboration and license agreement under which both companies will develop and commercialize highly selective, novel oral Syk inhibitors for the treatment of various autoimmune and inflammatory diseases, including rheumatoid arthritis and systemic lupus erythematosus. [Portola Pharmaceuticals, Inc.] Press Release TxCell Presents Final Positive Results of the Phase I/II Clinical Trial with Antigen-Specific Treg Cells in Crohn’s Disease TxCell SA announced the presentation of final positive results of the phase I/II study in Crohn’s disease (CATS-1) with its leading product candidate, OvaSave®. [TxCell SA] Press Release Xencor Initiates Phase I Study of XmAb®5871 Therapeutic Antibody for the Treatment of Autoimmune Diseases; Dual-Targeted Antibody Aims to Treat Lupus and Rheumatoid Arthritis by Suppressing Autoimmune Response Xencor, Inc. announced the initiation of a Phase 1 clinical trial of XmAb®5871, the company’s therapeutic antibody for the treatment of autoimmune diseases. [Xencor, Inc.] Press Release Selecta Announces $47.25 Million Financing to Broaden R&D Capabilities and Accelerate Pipeline of Vaccines and Immunotherapies Selecta Biosciences, Inc. announced that it has secured new funding from RUSNANO, existing investors, and additional new investors. RUSNAO entered as a significant new investor in Selecta in this new $47.25 million financing which will broaden Selecta’s research and development (R&D) capabilities and advance its new class of vaccines and immunotherapies. [Selecta Biosciences, Inc.] Press Release Activartis Develops Dendritic Cell-Based Therapeutic Cancer Vaccine in Phase II Activartis GmbH – former Trimed Biotech GmbH – is developing a cancer immunotherapy concept which is currently in phase II clinical trials. [B3C Newswire] Press Release |
|
|
|